AstraZeneca's Atacand Heart Failure Indication Clears FDA Ahead Of Cmte. Review
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency approves candesartan for treatment of heart failure to reduce cardiovascular mortality and hospitalizations. The angiotensin receptor blocker is the first product in its class to receive the claim. Approval comes two days before an FDA advisory panel review.